I-Mab to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

GlobeNewswire

02-04

I-Mab logo-EN.png

ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in Oppenheimer’s 35^th Annual Healthcare Life Sciences Conference, being held virtually, on February 11-12, 2025.

Details are as follows:

Oppenheimer’s 35^th Annual Healthcare Life Sciences Conference
Conference Date:		February 11-12, 2025
Format:		Company Presentation and one-on-one meetings
Presentation Time:		Tuesday, February 11, 2025, 4:00 to 4:30 PM ET
Webcast Link:		https://wsw.com/webcast/oppenheimer39/imab/2739496

About I-Mab

I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit us at: https://www.i-mabbiopharma.com/ and follow us on LinkedIn and X.

Investor & Media Contacts

PJ Kelleher
LifeSci Advisors
+1 617-430-7579
pkelleher@lifesciadvisors.com

IR@imabbio.com

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2508345580"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2508345580\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2508345580?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-04 20:30","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2508345580","market":"us","top_or_hot":-1,"title":"I-Mab to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference","media":"GlobeNewswire","content":"<html><body><img hspace=\"5\" src=\"https://s1.yimg.com/uu/api/res/1.2/y0il.Wp4rkHlUptHFsH61w--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/61ac48be92843ad3a8f6edb37f7d267b\" title=\"I-Mab logo-EN.png\" vspace=\"5\"/>\n<p>ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in Oppenheimer’s 35<sup>th</sup> Annual Healthcare Life Sciences Conference, being held virtually, on February 11-12, 2025.</p>\n<p>Details are as follows:</p>\n<table>\n<tbody>\n<tr>\n<td colspan=\"3\"><strong>Oppenheimer’s 35</strong><sup><strong>th</strong></sup><strong> Annual Healthcare Life Sciences Conference</strong></td>\n</tr>\n<tr>\n<td>Conference Date:</td>\n<td> </td>\n<td>February 11-12, 2025</td>\n</tr>\n<tr>\n<td>Format:</td>\n<td> </td>\n<td>Company Presentation and one-on-one meetings</td>\n</tr>\n<tr>\n<td>Presentation Time:</td>\n<td> </td>\n<td>Tuesday, February 11, 2025, 4:00 to 4:30 PM ET</td>\n</tr>\n<tr>\n<td>Webcast Link:</td>\n<td> </td>\n<td>https://wsw.com/webcast/oppenheimer39/imab/2739496</td>\n</tr>\n</tbody>\n</table>\n<p><strong>About I-Mab</strong></p>\n<p>I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit us at: https://www.i-mabbiopharma.com/ and follow us on LinkedIn and X.</p>\n<p><strong>Investor &amp; Media Contacts</strong></p>\n<p>PJ Kelleher<br/>LifeSci Advisors<br/>+1 617-430-7579<br/>pkelleher@lifesciadvisors.com<br/><br/><br/></p>\n<p>IR@imabbio.com</p>\n<br/></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>I-Mab to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nI-Mab to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">GlobeNewswire</strong><span class=\"h-time small\">2025-02-04 20:30</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><img hspace=\"5\" src=\"https://s1.yimg.com/uu/api/res/1.2/y0il.Wp4rkHlUptHFsH61w--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/61ac48be92843ad3a8f6edb37f7d267b\" title=\"I-Mab logo-EN.png\" vspace=\"5\"/>\n<p>ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in Oppenheimer’s 35<sup>th</sup> Annual Healthcare Life Sciences Conference, being held virtually, on February 11-12, 2025.</p>\n<p>Details are as follows:</p>\n<table>\n<tbody>\n<tr>\n<td colspan=\"3\"><strong>Oppenheimer’s 35</strong><sup><strong>th</strong></sup><strong> Annual Healthcare Life Sciences Conference</strong></td>\n</tr>\n<tr>\n<td>Conference Date:</td>\n<td> </td>\n<td>February 11-12, 2025</td>\n</tr>\n<tr>\n<td>Format:</td>\n<td> </td>\n<td>Company Presentation and one-on-one meetings</td>\n</tr>\n<tr>\n<td>Presentation Time:</td>\n<td> </td>\n<td>Tuesday, February 11, 2025, 4:00 to 4:30 PM ET</td>\n</tr>\n<tr>\n<td>Webcast Link:</td>\n<td> </td>\n<td>https://wsw.com/webcast/oppenheimer39/imab/2739496</td>\n</tr>\n</tbody>\n</table>\n<p><strong>About I-Mab</strong></p>\n<p>I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit us at: https://www.i-mabbiopharma.com/ and follow us on LinkedIn and X.</p>\n<p><strong>Investor &amp; Media Contacts</strong></p>\n<p>PJ Kelleher<br/>LifeSci Advisors<br/>+1 617-430-7579<br/>pkelleher@lifesciadvisors.com<br/><br/><br/></p>\n<p>IR@imabbio.com</p>\n<br/></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/mab-present-oppenheimer-35th-annual-123000412.html\">GlobeNewswire</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"USJW.SI","symbol_name":"ALPHAB 3xLongSG261006","start_time":0,"source_url":"https://finance.yahoo.com/news/mab-present-oppenheimer-35th-annual-123000412.html","article_id":"2508345580","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2508345580","pubTimestamp":1738672200,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"I-Mab  is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit us at: https://www.i-mabbiopharma.com/ and follow us on LinkedIn and X.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"USJW.SI":"ALPHAB 3xLongSG261006","TSYW.SI":"TESLA 3xLongSG261006","BK4505":"高瓴资本持仓","HCSG":"医疗保健服务",".IXIC":"NASDAQ Composite","QLD":"纳指两倍做多ETF","BK4127":"投资银行业与经纪业","BK4137":"综合支持服务","IMAB":"天境生物","PSQ":"纳指反向ETF","NVIW.SI":"NVDA 3xLongSG261006","BK4139":"生物科技","USAW.SI":"AMZN 3xLongSG261006","OPY":"奥本海默控股","BK4535":"淡马锡持仓","SQQQ":"纳指三倍做空ETF","QID":"纳指两倍做空ETF","TQQQ":"纳指三倍做多ETF","BK4526":"热门中概股"},"translate_title":"天境生物将出席奥本海默第35届年度医疗保健生命科学会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{".IXIC":0.67,"MNQmain":0.6,"NQmain":0.6,"HCSG":1,"IMAB":0.9,"NVIW.SI":0.6,"OPY":1,"PSQ":0.6,"QID":0.6,"QLD":0.6,"SQQQ":0.6,"TQQQ":0.6,"TSYW.SI":0.6,"USAW.SI":0.6,"USJW.SI":0.6},"content_text":"ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference, being held virtually, on February 11-12, 2025.\nDetails are as follows:\n\n\n\nOppenheimer’s 35th Annual Healthcare Life Sciences Conference\n\n\nConference Date:\n \nFebruary 11-12, 2025\n\n\nFormat:\n \nCompany Presentation and one-on-one meetings\n\n\nPresentation Time:\n \nTuesday, February 11, 2025, 4:00 to 4:30 PM ET\n\n\nWebcast Link:\n \nhttps://wsw.com/webcast/oppenheimer39/imab/2739496\n\n\n\nAbout I-Mab\nI-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit us at: https://www.i-mabbiopharma.com/ and follow us on LinkedIn and X.\nInvestor & Media Contacts\nPJ KelleherLifeSci Advisors+1 617-430-7579pkelleher@lifesciadvisors.com\nIR@imabbio.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}